← All trials
NCT06907173
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 31, 2025
- Primary completion
- Jun 30, 2029
- Completion date
- Dec 31, 2029
- First posted
- Apr 2, 2025
- Last posted
- Apr 2, 2025
- Enrollment
- 770
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of VirginiaLead sponsor
- Harvard UniversityCollaborator
- University of VirginiaOfficial
- University of MichiganCollaborator
- Georgetown UniversityCollaborator
- University of VirginiaSponsor investigator
- Medical University of South CarolinaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.